Multiparametric magnetic resonance imaging of the prostate can improve the predictive value of the urinary prostate cancer antigen 3 test in patients with elevated prostate-specific antigen levels and a previous negative biopsy

BJU International

Volumn 110, Issue 11, 2012, Pages 1661-1665

  Sciarra, Alessandro ^a   Panebianco, Valeria ^a   Cattarino, Susanna ^a   Busetto, Gian Maria ^a   De Berardinis, Ettore ^a   Ciccariello, Mauro ^a   Gentile, Vincenzo ^a   Salciccia, Stefano ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

imaging; initial diagnosis; magnetic resonance; markers; prostate neoplasm

Indexed keywords

PROSTATE ANTIGEN; PROSTATE CANCER ANTIGEN 3; PROSTATE SPECIFIC ANTIGEN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE BIOPSY; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; RECEIVER OPERATING CHARACTERISTIC; REPEAT PROCEDURE; SENSITIVITY AND SPECIFICITY; TRANSRECTAL ULTRASONOGRAPHY; URINALYSIS;

EID: 85027930191     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2012.11146.x     Document Type: Article

References (23)

1. Heidenreich A, Bolla M, Joniau S, et al,. EAU guidelines on prostate cancer. European Association of urology. Eur Urol 2011; 53: 68-80
2. Harris R, Lohr KN,. Screening for prostate cancer: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002; 137: 917-29
3. Kawachi MH, Bahnson RR, Barry M, et al,. Prostate cancer early detection. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 2007; 7: 714-36
4. Ficarra V, Novara G, Zattoni F,. The role of the prostate cancer antigen 3 (PCA3) test for the diagnosis of prostate cancer in the era of opportunistic prostate-specific antigen screening. Eur Urol 2010; 58: 482-4
5. Bussemakers MJ, van Bokhoven A, Verhaegh GW, et al,. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 1999; 59: 5975-9
6. de Kok JB, Verhaegh GW, Roelofs RW, et al,. DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res 2002; 62: 2695-8
7. Hessels D, Klein Gunnewiek JM, van Oort I, et al,. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 2003; 44: 8-15
8. Fradet Y, Saad F, Aprikian A, et al,. uPM3, a new molecular urine test for the detection of prostate cancer. Urology 2004; 64: 311-5
9. Ruiz-Aragon J, Marquez-Pelaez S,. Assessment of the PCA3 test for prostate cancer diagnosis. A systematic review and meta-analysis. Actas Urol Esp 2010; 34: 346-55
10. Marks LS, Fradet Y, Deras IL, et al,. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology 2007; 69: 532-5
11. Deras IL, Aubin SM, Blase A, et al,. PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol 2008; 179: 1587-92
12. Haese A, de la Taille A, van Poppel H, et al,. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol 2008; 54: 1081-8
13. Nakanishi H, Groskopf J, Fritsche HA, et al,. PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance. J Urol 2008; 179: 1804-9
14. Hricak H,. MR imaging and MR spectroscopic imaging in the pretreatment evaluation of prostate cancer. Br J Radiol 2005; 78: 103-11
15. Sciarra A, Barentsz J, Bjartell A, et al,. Advances in magnetic resonance imaging: how they are changing the management of prostate cancer. Eur Urol 2011; 6: E33-8
16. Cirillo S, Petracchini M, Della Monica P, et al,. Value of endorectal MRI and MRS in patients with elevated prostate-specific antigen levels and previous negative biopsies to localize peripheral zone tumors. Clin Radiol 2008; 63: 871-9
17. Sciarra A, Panebianco M, Ciccariello M, et al,. Value of magnetic resonance spectroscopy imaging and dynamic contrast-enhanced imaging for detecting prostate cancer foci in men with prior negative biopsy. Clin Cancer Res 2010; 16: 1875-83
18. Lawrentschuk N, Fleshner N,. The role of magnetic resonance imaging in targeting prostate cancer in patients with previous negative biopsies and elevated prostate specific antigen levels. BJU Int 2008; 103: 730-3
19. Roobol MJ, Schröder FH, van Leeuwen P, et al,. Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: exploring the value of PCA3 for a first-line diagnostic test. Eur Urol 2010; 58: 475-81
20. Sciarra A, Panebianco V, Salciccia S,. Role of dynamic contrast enhanced magnetic resonance (MR) imaging and proton MR spec spectroscopic imaging in the detection of local recurrence after radical prostatectomy for prostate cancer. Eur Urol 2008; 54: 589-600
21. Wefer AE, Hricak H, Vigneron DB, et al,. Sextant localization of prostate cancer: comparison of sextant biopsy, magnetic resonance imaging and magnetic resonance spectroscopic imaging with step section histology. J Urol 2000; 164: 400-4
22. Testa C, Schiavina R, Lodi R, et al,. Prostate cancer: sextant localization with MR imaging, MR spectroscopy, and 11c-choline PET/TC. Radiology 2007; 244: 797-806
23. Fütterer JJ, Heijmink SW, Scheenen TW, et al,. Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. Radiology 2006; 241: 449-58